186 related articles for article (PubMed ID: 30548583)
1. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
Redondo AM; Valcárcel D; González-Rodríguez AP; Suárez-Lledó M; Bello JL; Canales M; Gayoso J; Colorado M; Jarque I; Del Campo R; Arranz R; Terol MJ; Rifón JJ; Rodríguez MJ; Ramírez MJ; Castro N; Sánchez A; López-Jiménez J; Montes-Moreno S; Briones J; López A; Palomera L; López-Guillermo A; Caballero D; Martín A;
Br J Haematol; 2019 Mar; 184(5):797-807. PubMed ID: 30548583
[TBL] [Abstract][Full Text] [Related]
2. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Noesslinger T; Panny M; Simanek R; Moestl M; Boehm A; Menschel E; Koller E; Keil F
Eur J Haematol; 2018 Sep; 101(3):326-331. PubMed ID: 29799642
[TBL] [Abstract][Full Text] [Related]
3. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Saleh K; Danu A; Koscielny S; Legoupil C; Pilorge S; Castilla-Llorente C; Ghez D; Lazarovici J; Michot JM; Khalife-Saleh N; Lapierre V; Alenxandrova K; Arfi-Rouche J; Bourhis JH; Ribrag V
Leuk Lymphoma; 2018 Nov; 59(11):2580-2587. PubMed ID: 29164977
[TBL] [Abstract][Full Text] [Related]
4. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
5. Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
Farnault L; Venton G; Pourroy B; Jourde-Chiche N; Ivanov V; Arcani R; Roche P; Mercier C; Colle J; Fanciullino R; Costello RT
Bone Marrow Transplant; 2019 Jul; 54(7):1173-1175. PubMed ID: 30718799
[No Abstract] [Full Text] [Related]
6. Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Mei M; Wondergem MJ; Palmer JM; Shimoni A; Hasenkamp J; Tsai NC; Simpson J; Nademanee A; Raubitschek A; Forman SJ; Krishnan AY
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2072-5. PubMed ID: 25079874
[TBL] [Abstract][Full Text] [Related]
7. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
Przepiorka D; van Besien K; Khouri I; Hagemeister F; Samuels B; Folloder J; Ueno NT; Molldrem J; Mehra R; Körbling M; Giralt S; Gajewski J; Donato M; Cleary K; Claxton D; Braunschweig I; Andersson B; Anderlini P; Champlin R
Ann Oncol; 1999 May; 10(5):527-32. PubMed ID: 10416001
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
Martín A; Fernández-Jiménez MC; Caballero MD; Canales MA; Pérez-Simón JA; García de Bustos J; Vázquez L; Hernández-Navarro F; San Miguel JF
Br J Haematol; 2001 Apr; 113(1):161-71. PubMed ID: 11328296
[TBL] [Abstract][Full Text] [Related]
10. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Wu R; Ma L
Cell Transplant; 2023; 32():9636897231179364. PubMed ID: 37350429
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
Kim DY; Chung JS; Jo JC; Cho SH; Shin HJ
Ann Hematol; 2020 Apr; 99(4):819-828. PubMed ID: 32025840
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
O'Meara A; Halter J; Heim D; Gerull S; Bucher C; Passweg J; Buser A; Stern M
Biol Blood Marrow Transplant; 2013 Jan; 19(1):82-6. PubMed ID: 22897965
[TBL] [Abstract][Full Text] [Related]
13. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
Sugimoto M; Ito S; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Ashizawa M; Yamamoto C; Fujiwara S; Okazuka K; Hatano K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kako S; Kanda Y
Ann Hematol; 2016 Sep; 95(9):1513-9. PubMed ID: 27365141
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
Vose JM; Bierman PJ; Loberiza FR; Enke C; Hankins J; Bociek RG; Chan WC; Weisenburger DD; Armitage JO
Biol Blood Marrow Transplant; 2013 Jan; 19(1):123-8. PubMed ID: 22940055
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
16. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
18. BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.
Gilli S; Novak U; Taleghani BM; Baerlocher GM; Leibundgut K; Banz Y; Zander T; Betticher D; Egger T; Rauch D; Pabst T
Ann Hematol; 2017 Mar; 96(3):421-429. PubMed ID: 28011985
[TBL] [Abstract][Full Text] [Related]
19. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]